No Data
No Data
We Believe That PharmaResources (Shanghai)'s (SZSE:301230) Weak Earnings Are A Good Indicator Of Underlying Profitability
Hengbo Pharmaceutical (301230.SZ): China Wealth Foundation intends to reduce its shareholding by no more than 1.00%.
On September 2nd, Gelonghui announced that as of the disclosure date of this announcement, Peking Zhongfu Jishi Investment Center (Limited Partnership), referred to as 'Zhongfu Jishi', holds 6,164,860 shares of the company, accounting for 4.48% of the total share capital after deducting the shares held by the company's repurchase account disclosed most recently. Together with Beijing Zhongfu Chengzhang Private Equity Investment Center (Limited Partnership), the consistent actor, they collectively hold 8,967,660 shares of the company, accounting for 6.52% of the total share capital after deducting the shares held by the company's repurchase account disclosed most recently. Zhongfu Jishi plans to trade starting from the date of this announcement for 15 trading days, and then continue for 3 more.
Hongbo Pharmaceutical: 2024 Semi-Annual Report Summary
Hongbo Pharmaceutical: 2024 Semi-Annual Report
PharmaResources (Shanghai) Co., Ltd.'s (SZSE:301230) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Hongbo Pharmaceutical (301230.SZ): Intends to acquire the partnership equity of Lichen Yuanding held by Hainan Tongying.
On August 12th, Gelunhui announced that Hongbo Pharmaceuticals (301230.SZ) has recently signed an agreement with one of its limited partners, Hainan Tongying Industrial Technology Partnership Enterprise (Limited Partnership) (hereinafter referred to as 'Hainan Tongying'), on the transfer of equity in the Shanghai Lichenyuanding Private Equity Investment Partnership Enterprise (Limited Partnership) between Hainan Tongying and Shanghai Hongbo Zhiyuan Pharmaceuticals Co., Ltd. The company plans to acquire 10 million yuan of partnership equity of Lichenyuanding held by Hainan Tongying for 0 yuan (0 yuan paid-in capital), and the transfer of partnership equity will be completed during this period.
No Data
No Data